跳转至内容
Merck
  • Effects of orally administered moxaverine on ocular blood flow in healthy subjects.

Effects of orally administered moxaverine on ocular blood flow in healthy subjects.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2012-12-04)
Doreen Schmidl, Berthold Pemp, Michael Lasta, Agnes Boltz, Semira Kaya, Stefan Palkovits, Franz Prager, Leopold Schmetterer, Gerhard Garhofer
摘要

To investigate the effect of orally administered moxaverine (Kollateral forte®) on ocular blood flow in young healthy subjects. Sixteen healthy subjects (eight male/eight female) aged between 20 and 32 years were included in this placebo-controlled, double-masked, two-way crossover study. Volunteers received 900 mg moxaverine-hydrochloride administered orally in three equal doses or placebo identical in appearance on 2 study days. Outcome variables were measured at baseline and 5 h after first drug administration. Laser Doppler flowmetry was used to assess choroidal and optic nerve head blood flow. Blood velocities in the retrobulbar vessels were measured with color Doppler imaging. Neither moxaverine nor placebo changed mean arterial pressure or intraocular pressure. Neither moxaverine nor placebo had an effect on choroidal (moxaverine: by 9.5 ± 17.2 %, placebo 3.8 ± 18.8 %, p = 0.54 between groups) or optic nerve head blood flow (moxaverine: 4.8 ± 10.4 %, placebo: 1.8 ± 10.9 %, p = 0.52 between groups). Similarly, administration of moxaverine did not change blood flow velocities or calculated resistance index in the retrobulbar vessels compared to placebo. The data of the present study indicate that orally administered moxaverine does not increase ocular blood flow. This is in contrast to previous findings, where parenteral administration of moxaverine lead to a significant increase in choroidal blood flow and blood flow velocities in the retrobulbar vessels. The reason for these differing results is unclear, but may be related to the low bioavailability after oral administration.

材料
货号
品牌
产品描述

Sigma-Aldrich
罂粟碱 盐酸盐, powder
登录查看公司和协议定价
货号包装规格是否有货价格
20 reactions
有货
发货地 SAINT LOUIS
$60.50
100 reactions
预计发货时间 February 27, 2026
发货地 SAINT LOUIS
$192.00
800 reactions
预计发货时间 March 04, 2025
发货地 SAINT LOUIS
$1,230.00

如需订购该产品,请通过联系信息 联系默克当地经销商。

Supelco
罂粟碱 盐酸盐, Pharmaceutical Secondary Standard; Certified Reference Material
登录查看公司和协议定价
货号包装规格是否有货价格
20 reactions
有货
发货地 SAINT LOUIS
$60.50
100 reactions
预计发货时间 February 27, 2026
发货地 SAINT LOUIS
$192.00
800 reactions
预计发货时间 March 04, 2025
发货地 SAINT LOUIS
$1,230.00

如需订购该产品,请通过联系信息 联系默克当地经销商。

罂粟碱 盐酸盐, European Pharmacopoeia (EP) Reference Standard
登录查看公司和协议定价
货号包装规格是否有货价格
20 reactions
有货
发货地 SAINT LOUIS
$60.50
100 reactions
预计发货时间 February 27, 2026
发货地 SAINT LOUIS
$192.00
800 reactions
预计发货时间 March 04, 2025
发货地 SAINT LOUIS
$1,230.00

如需订购该产品,请通过联系信息 联系默克当地经销商。